Pharmacologic class (EPC) · 9 drug pages

Serotonin-1b and Serotonin-1d receptor agonist: adverse event reports filed with FDA

27,938 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

27,938
reports across the class: 0.1% of all reports; 1,698
reports, 12 months to June 2026: 1,349 in the 12 months before; 48%
marked serious by the reporter: 57.4% across all reports; 9
drugs with a page: brand and generic names counted separately

Serotonin-1b and Serotonin-1d receptor agonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 9 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 27,938 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026.

1,698 reports arrived in the 12 months to June 2026, up 26% from 1,349 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 48% of the class's reports are marked serious, 2.3% record death among the outcomes and 14.7% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug ineffective (25.2%), headache (10.2%) and migraine (9.9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
ImitrexSumatriptan	brand	7,491	76	21.7%	Drug ineffective
Sumatriptan	generic	6,690	556	63.3%	Drug ineffective
Sumatriptan succinate	generic	3,580	365	40.8%	Drug ineffective
RelpaxEletriptan hydrobromide	brand	3,383	22	50.1%	Drug ineffective
MaxaltRizatriptan benzoate	brand	1,962	217	67%	Drug ineffective
ZomigZolmitriptan	brand	1,922	29	43.3%	Migraine
Rizatriptan	generic	1,105	182	71.6%	Drug ineffective
Zolmitriptan	generic	1,037	142	88.1%	Headache
Rizatriptan benzoate	generic	768	109	69.5%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug ineffectivethe medicine did not work as expected25.2%7,029
Headachehead pain10.2%2,838
Migrainemigraine9.9%2,768
Nauseafeeling sick7.5%2,108
Off label useused for a purpose or in a way not on the label6.5%1,815
Drug intolerancethe medicine was not tolerated4.1%1,151
Product use in unapproved indicationused for a purpose not on the label4.1%1,146
Vomitingbeing sick4.1%1,136
Product quality issuea problem with the product itself3.9%1,094
Hypersensitivityan allergic-type reaction3.8%1,073
Dizzinesslight-headedness or unsteadiness3.6%1,016
Drug hypersensitivityan allergic-type reaction to a medicine3.6%1,004
Dyspnoeashortness of breath3.1%854
Swollen tongue2.9%818
Swelling facea swollen face2.9%814
Hyperhidrosisexcessive sweating2.9%813
Painpain, site not specified2.8%795
Angioedemadeep swelling of skin or mucous membranes2.8%792
Malaisegeneral feeling of being unwell2.8%786
Dysphoniaa hoarse voice2.8%773
Drug ineffective for unapproved indication2.7%765
Fatiguetiredness2.5%710
Chest discomfortchest discomfort2.5%701
Product dose omission issuea dose was missed2.4%675
Chest painchest pain2.4%664

Solid bar: share of all class reports. Hollow bar: the median share across the 9 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death2.3%632

Life-threatening3%838

Hospitalisation (initial or prolonged)14.7%4,094

Disability2.4%657

Congenital anomaly1.3%365

Other serious36.6%10,216

Not serious52%14,531

Patient age

Under 20.6%175

2 to 110.3%94

12 to 171.4%383

18 to 4422.3%6,224

45 to 6423.3%6,516

65 to 743.9%1,101

75 and over1%282

Age not given47.1%13,163

Who reported

Physician17%4,743

Pharmacist5.8%1,631

Other health professional16.9%4,713

Lawyer0.2%45

Consumer or non-health professional56.2%15,692

Not given4%1,114

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Serotonin-1b and Serotonin-1d receptor agonist reports

Which drugs are in the Serotonin-1b and Serotonin-1d receptor agonist class on this site?

Imitrex, Sumatriptan, Sumatriptan succinate, Relpax, Maxalt and Zomig and 3 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

27,938 reports through June 2026, 1,698 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug ineffective (25.2%), headache (10.2%), migraine (9.9%), nausea (7.5%) and off label use (6.5%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.